Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 110 results for anticoagulation

  1. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  2. Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

    Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.

  3. Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (IPG651)

    Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg in adults. This involves removing the clot through a catheter inserted into the vein.

  4. Aspirin and anticoagulant treatment for acute ischaemic stroke: Does modified-release dipyridamole or clopidogrel with aspirin improve outcome compared with aspirin alone when administered early after acute ischaemic stroke?

    ischaemic stroke improves outcome compared with no treatment or early anticoagulation. In the secondary prevention of stroke, the...

  5. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  6. Utilising the skills of the clinical pharmacist within the MDT for improved medicines optimisation

    during admission. Medicines reconciliation completed. Discussion with anticoagulation clinic regarding appropriate dose for discharge...

  7. Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation (IPG294)

    Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation. This involves using heat to destroy selected areas of the heart to prevent the abnormal electrical impulses responsible for atrial fibrillation.

  8. Overprescribing of rivaroxaban in non-atrial fibrillation patients in primary care

    stating a duration of therapy in discharge correspondence concerning anticoagulation. This project may be extended to cover all DOACs,...

  9. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (IPG472)

    Evidence-based recommendations on percutaneous closure of the patent foramen ovale for the prevention of cerebral embolic stroke. This involves placing a small device into the heart to close the hole.

  10. Zio XT for detecting cardiac arrhythmias (MTG52)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

  11. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

  12. Interventional procedures advisory committee members

    Interventional Procedures Advisory Committee members

  13. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  14. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  15. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.